Search

Your search keyword '"Son, Byung Ho"' showing total 18 results
Start Over Author "Son, Byung Ho" Journal scientific reports
18 results on '"Son, Byung Ho"'

2. Longitudinal dynamics of circulating tumor DNA for treatment monitoring in patients with breast cancer recurrence

Author

Yoo, Tae-Kyung Robyn, Lee, Ji-Young, Park, Hwan, Cho, Whi-Kyung, Jeon, Seyeon, Jun, Ha Ra, Lee, Sae Byul, Chung, Il Yong, Kim, Hee Jeong, Ko, Beom Seok, Lee, Jong Won, Son, Byung Ho, Ahn, Sei-Hyun, Jeong, Jae Ho, Kim, Jeong Eun, Ahn, Jin-Hee, Jung, Kyung Hae, Kim, Sung-Bae, Lee, Hee Jin, Gong, Gyungyub, Kim, Jisun, and Chun, Sung-Min

Published
2024
Full Text
View/download PDF

4. Use of the Da Vinci SP surgical system in robot-assisted nipple-sparing mastectomy: a single-center, retrospective study.

Author

Lee, Sae Byul, Kim, Jisun, Chung, Il Yong, Kim, Hee Jeong, Lee, Jong Won, Son, Byung Ho, and Ko, Beom Seok

Subjects
SURGICAL site, SURGICAL complications, PLASTIC surgeons, CANCER relapse, MAMMAPLASTY, SURGICAL robots
Abstract

We investigated the safety and performance of the Da Vinci SP single-port robot (SP robot) in nipple-sparing mastectomy (NSM) with immediate reconstruction. Medical records of 60 women aged ≥ 19 years who had undergone SP robot-assisted unilateral or bilateral NSM with immediate reconstruction between October 2020 and August 2021 were retrospectively analyzed. Stage I (31, 47.1%) was the most common pathological tumor-node-metastasis stage, followed by stages II (22, 33.3%), 0 (7, 10.6%), and III (4, 6.0%). The median total duration of NSM performed by a breast surgeon and reconstruction performed by a plastic surgeon was 154.0 min (interquartile range [IQR], 130.5–206.0 min) and 133.0 min (IQR, 80.0–255.0 min), respectively. The median length of hospitalization was 5.5 days (IQR, 3.0–9.0 days). Conversion to robotic multiport or open surgery was not required in any case. The median duration to drain removal was 5.0 days (IQR, 4.0–6.0 days). Recurrence of cancer within 6 months was not observed in any patient. SP robot-assisted NSM with immediate reconstruction was performed successfully in all patients without conversion to open surgery or the incidence of significant perioperative complications, indicating its precision and ability to minimize the size of the surgical incision. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

5. Prognosis of patients with breast cancer who underwent breast-conserving surgery using a 3D-printed surgical guide after neoadjuvant chemotherapy.

Author

Kim, Ah Yoon, Lee, Sae Byul, Yoo, Tae Kyung, Kim, Ji Sun, Chung, Il Yong, Kim, Hee Joung, Lee, Jong Won, Son, Byung Ho, Jeong, Jae Ho, Lee, Hee Jin, Kim, Nam kug, and Ko, BeomSeok

Subjects
BREAST cancer surgery, LUMPECTOMY, BREAST cancer prognosis, MEDICAL sciences, NEOADJUVANT chemotherapy, BREAST
Abstract

In breast-conserving surgery (BCS), clear resection margins are crucial to prevent recurrence. Accurate imaging is vital for precise BCS, with MRI being the most accurate. However, MRI has limitations in identifying the exact extent of breast cancer in patients who have undergone neoadjuvant chemotherapy (NACT). A 3D-Printed Breast Surgical Guide (3DP-BSG) can address this issue by effectively pinpointing cancer extent in NACT patients, thus enhancing surgical accuracy. This retrospective single-institution cohort study focused on female patients diagnosed with invasive breast cancer who underwent NACT. Between November 2015 and October 2021, patients received BCS with the aid of a 3DP-BSG. Personalized 3DP-BSG targeted tumors by tracking changes in breast and tumor anatomy on MRI before and after NACT. 203 patients with invasive breast cancer were enrolled in the study. According to exclusion criteria, 197 patients were analyzed. The median follow-up period was 35.3 months (range: 2.2–96.8 months). 3 patients (1.5%) had positive resection margins. During the follow-up period, 17 patients (8.6%) experienced recurrence, with one patient (0.5%) confirmed local recurrences. The application of MRI-based 3DP-BSG is effective in achieving low positive margins and local recurrence in patients undergoing BCS after NACT, offering a promising approach for improving surgical outcomes. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

8. Publisher Correction: Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients

Author

Gwark, Sungchan, Kim, Jisun, Kwon, Nak-Jung, Kim, Kyoung-Yeon, Kim, YongNam, Lee, Cham Han, Kim, Young Hun, Kim, Myoung Shin, Hong, Sung Woo, Choi, Mi Young, Jeon, Byung Hee, Chang, Suhwan, Yu, Jonghan, Park, Ji Yeon, Lee, Hee Jin, Lee, Sae Byul, Chung, Il Yong, Ko, Beom Seok, Kim, Hee Jeong, Lee, Jong Won, Son, Byung Ho, Ahn, Jin-Hee, Jung, Kyung Hae, Kim, Sung-Bae, Gong, Gyung-Yub, and Ahn, Sei Hyun

Published
2021
Full Text
View/download PDF

13. Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients

Author

Gwark, Sungchan, Kim, Jisun, Kwon, Nak-Jung, Kim, Kyoung-Yeon, Kim, YongNam, Lee, Cham Han, Kim, Young Hun, Kim, Myoung Shin, Hong, Sung Woo, Choi, Mi Young, Jeon, Byung Hee, Chang, Suhwan, Yu, Jonghan, Park, Ji Yeon, Lee, Hee Jin, Lee, Sae Byul, Chung, Il Yong, Ko, Beom Seok, Kim, Hee Jeong, Lee, Jong Won, Son, Byung Ho, Ahn, Jin-Hee, Jung, Kyung Hae, Kim, Sung-Bae, Gong, Gyung-Yub, and Ahn, Sei Hyun

Published
2020
Full Text
View/download PDF

18. Association between tumor 18F-fluorodeoxyglucose metabolism and survival in women with estrogen receptor-positive, HER2-negative breast cancer.

Author

Chae, Sun Young, Park, Seol Hoon, Lee, Hyo Sang, Ahn, Jin-Hee, Kim, Sung-Bae, Jung, Kyung Hae, Kim, Jeong Eun, Ahn, Sei Hyun, Son, Byung Ho, Lee, Jong Won, Ko, Beom Seok, Kim, Hee Jeong, Gong, Gyungyub, Oh, Jungsu S., Park, Seo Young, and Moon, Dae Hyuk

Subjects
POSITRON emission tomography, BREAST cancer, COMPUTED tomography, ESTROGEN receptors, NEOADJUVANT chemotherapy
Abstract

We examined whether 18F-fluorodeoxyglucose metabolism is associated with distant relapse-free survival (DRFS) and overall survival (OS) in women with estrogen receptor (ER)-positive, HER2-negative breast cancer. This was a cohort study examining the risk factors for survival that had occurred at the start of the study. A cohort from Asan Medical Center, Korea, recruited between November 2007 and December 2014, was included. Patients received anthracycline-based neoadjuvant chemotherapy. The maximum standardized uptake value (SUV) of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) was measured. The analysis included 466 women. The median (interquartile range) follow-up period without distant metastasis or death was 6.2 (5.3–7.6) years. Multivariable analysis of hazard ratio (95% confidence interval [CI]) showed that the middle and high tertiles of SUV were prognostic for DRFS (2.93, 95% CI 1.62–5.30; P < 0.001) and OS (4.87, 95% CI 1.94–12.26; P < 0.001). The 8-year DRFS rates were 90.7% (95% CI 85.5–96.1%) for those in the low tertile of maximum SUV vs. 73.7% (95% CI 68.0–79.8%) for those in the middle and high tertiles of maximum SUV. 18F-fluorodeoxyglucose PET/CT may assess the risk of distant metastasis and death in ER-positive, HER2-negative patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results